The ABPI today welcomes the publication of technical notices issued by the Government and the letter from the Department of Health and Social Care on medicines supply contingency planning. This gives guidance to pharmaceutical companies as they prepare for Brexit.
Health experts in the UK have identified what they believe to be the ten most important and impactful medicines and vaccines introduced in to the NHS in the past 70 years.
The MHRA has published technical guidance on what a Brexit implementation period means for the life sciences sector, once finalised as part of the Withdrawal Agreement.
Yesterday, the European Medicines Agency (EMA) announced that it will further temporarily scale back and suspend activities in preparation for Brexit. The EMA said that it expects a staff loss of about 30%.
The Court has today made a judgment on the use of Avastin to treat a condition called wet age-related macular degeneration (wet AMD).
The Association of the British Pharmaceutical Industry (ABPI) and the AHSN Network today announce a new, five-year partnership to accelerate the introduction and uptake of transformative biomedical innovations into the NHS.
The Migration Advisory Committee (MAC) has published a report on the impact of European migration and its recommendations for the UK’s post-Brexit work immigration system.
The ABPI has responded to BMJ research into compliance with reporting the results of clinical trials.
The Northern Ireland Department of Health has announced that Northern Ireland (NI) patients will have the same access to new cancer medicines as patients in England.
The Migration Advisory Committee (MAC) has released a report on the impact of international students in the UK with recommendations on what an immigration system for students should look like post-Brexit.